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Neurologic complications are serious complications after hematopoietic stem cell transplantation (HSCT) and
signiﬁcantly contribute to morbidity and mortality. The purpose of this study was to investigate the clinical
features and prognosis in pediatric patients who had neurologic complications after allogeneic HSCT. We
retrospectively reviewed the medical records of children and adolescents (19 years old or younger) who un-
derwent allogeneic HSCT at our institution from 2000 to 2012. A total of 383 patients underwent 430 allogeneic
transplantations. Among them, 73 episodes of neurologic complications occurred in 70 patients. The cumulative
incidence of neurologic complications at day 400 was 20.0%. Almost two thirds of the episodes (63.0%, 46 of 73)
occurred within 100 days after transplantation. Calcineurin inhibitorerelated neurotoxicity was observed as the
most common cause of neurotoxicity (47.9%, 35 of 73) and was signiﬁcantly associated with earlier onset
neurologic complications, seizure, and tremor. It also showed a signiﬁcant association with lower probability of
headache, abnormality of cranial nerve, and neurologic sequelae. In a multivariate analysis, days to neutrophil
engraftment after HSCT, extensive chronic graft-versus-host disease (GVHD) and the existence of neurologic
sequelae were identiﬁed as risk factors for mortality in patients who had neurologic complications (hazard ratio
[HR], 1.08; 95% conﬁdence interval [CI], 1.02 to 1.15; P ¼ .011; HR, 5.98; 95% CI, 1.71 to 20.90; P ¼ .005; and HR,
4.37; 95% CI, 1.12 to 17.05; P ¼ .034, respectively). However, there was no signiﬁcant difference in the 5-year
overall survival between the patients who had neurologic complications without sequelae and the patients
who did not have any neurologic complications (57.3% versus 61.8%, P ¼ .906). In conclusion, we found that the
major signiﬁcant risk factors for mortality in pediatric recipients with neurologic complications were the ex-
istence of neurologic sequelae and extensive chronic GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION they contribute to morbidity and mortality after HSCT
Hematopoietic stem cell transplantation (HSCT) is a
curative treatment modality for many malignancies and
other life-threatening diseases. Since Thomas et al. per-
formed the ﬁrst HSCT in 1957, it is estimated that over 18,000
HSCT are performed annually worldwide [1,2].
Cytotoxicity related to conditioning regimens, the use of
immunosuppressive agents to modulate the recipient’s im-
mune system, and the alloreactivity of donor cells often lead
to serious complications after allogeneic HSCT. Neurologic
complications, mainly in the central nervous system (CNS),
are 1 of the most serious complications [3-5]. The incidence
of neurologic complications ranges from 9.7% to 65% anddgments on page 1097.
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ty for Blood and Marrow Transplantation.[4,6-12]. Signiﬁcant risk factors for neurologic complications
are allogeneic HSCT, unrelated donors, and high-grade
(>grade 2) acute graft-versus-host disease (GVHD) [7-13].
However, the factors affectingmortality among patients with
neurologic complications have not been well identiﬁed,
especially in the pediatric population. Furthermore, in the
majority of previous studies assessing neurologic complica-
tions, which were referred to as clinically signiﬁcant or life-
threatening neurologic events, the incidence of neurologic
complications might be underestimated. Nevertheless, there
is no suggested classiﬁcation or guideline for the evaluation
of neurologic complication after HSCT.
Therefore, we investigated the incidence and clinical
features of neurologic complications after allogeneic HSCT in
the pediatric population. The main objective of this study
was to evaluate the prognosis and risk factors for mortality in
pediatric patients with neurologic complications after allo-
geneic HSCT.
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Study Population
We deﬁned an episode of neurologic complication as an event asso-
ciated with new-onset neurologic symptom and corresponding abnormal
ﬁndings on diagnostic tests. From January 2000 to December 2012, we
investigated pediatric patients who underwent allogeneic HSCT for ma-
lignant and nonmalignant hematologic diseases at Samsung Medical
Center in Seoul, South Korea. All patients were 19 years of age or younger
at the time of allogeneic HSCT. Among these patients, we selected those
who received at least 1 neurologic diagnostic test within 400 days after
HSCT by searching the code number of diagnostic tests including brain
magnetic resonance imaging, brain computed tomography, electroen-
cephalography, nerve conduction study, and cerebrospinal ﬂuid exami-
nation during the period. We then reviewed the medical records of these
patients to identify episodes featuring new-onset neurologic complica-
tions. The patients who received neurologic diagnostic tests due to pre-
existing neurologic disease, head trauma, and mild or nonspeciﬁc
events subsiding within 24 hours were excluded. This study was approved
by the institutional review board at Samsung Medical Center, and the
requirement for informed consent was waived because of the retrospec-
tive nature of the study.
Data Collection
We included patients with CNS-positive leukemia in our study. Cra-
niospinal irradiation (cranial radiation therapy 2400 cGy, spinal radiation
therapy 600 cGy) was performed from the start of consolidation
chemotherapy for patients with CNS leukemia. No patients received post-
transplantation intrathecal chemotherapy. We reviewed baseline clinical
and demographic characteristics including age, sex, underlying disease,
type of donor, source of stem cell, intensity of conditioning regimen,
GVHD prophylaxis, use of high-dose total body irradiation (TBI), use of
antithymocyte globulin (ATG), and the grade of acute and chronic GVHD
in the identiﬁed cases of neurologic complications. To standardize the
neurologic complications, we selected neurologic events at and above
grade 2 toxicity according to the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0. Grade 2 CTCAE toxicity denotes
moderate severity that limits self-care activities of daily living. We
considered these criteria to be clinically informative because clinicians
should be concerned about neurologic events and their sequelae when
the severity of neurologic complications meets the CTCAE grade 2 or
above. Neurologic symptoms based on depressed level of consciousness
or pyramidal tract dysfunction, weakness, and sensory, behavior, and
speech impairment were regarded as neurologic events. Based on pre-
vious studies on neurologic complications after allogeneic HSCT, the
etiologies of the neurologic complications were classiﬁed into the
following 7 groups [3,7,13,14]: (1) calcineurin inhibitor (CNI)erelated
neurotoxicity, which presented as posterior reversible encephalopathy
syndrome (PRES) and/or toxic encephalopathy with symmetrically
reduced diffusion in the periventricular and supraventricular white
matter in brain magnetic resonance imaging diffusion ﬁndings without
any deﬁnite etiologies; (2) infectious diseases, deﬁned by the detection of
pathogens in cerebrospinal ﬂuid upon a culture and/or polymerase chain
reaction (PCR). In case of fungal infection, we used revised deﬁnition
of European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group Consensus Group [15,16];
(3) disease progression caused by CNS relapse of underlying disease; (4)
post-transplantation lymphoproliferative disorder (PTLD); (5) metabolic
disturbances; (6) vascular disorders (intracranial hemorrhage, throm-
bosis); and (7) others. We also assessed the existence of neurologic
sequelae due to neurologic complications at 6 months after the onset of
neurologic events. For convenience, we categorized the degree of
disability to 5 scales using the modiﬁed Rankin Scale (mRS), which is
widely used for the evaluation of stroke patients: (1) none, mRS 0 (no
clinical symptoms with or without resolution of lesions on neuro-
imaging studies); (2) mild, mRS 1 and 2 (no signiﬁcant disability and
slight disability, respectively, able to manage without assistance despite
symptoms); (3) moderate, mRS 3 and 4 (moderate and moderately severe
disability, respectively, requiring some help and in some cases needing
assistance to walk); (4) severe, mRS 5 (severe disability, requiring con-
stant nursing care and attention, bedridden, incontinent); and (5) death,
mRS 6 [17].
Conditioning Regimen and GVHD Prophylaxis
The conditioning regimens were determined by underlying disease, age,
and status according to the protocols. The intensity of conditioning was
determined by the patient baseline state and the state of underlying disease.
We divided patients by the intensity of conditioning into a myeloablativegroup and a reduced-intensity group according to the protocols. High dose-
TBI (total of 10 Gy) and busulfan (16 mg/kg for an oral dose or 12.8 mg/kg
for an intravenous dose) were usually regarded as the myeloablative con-
ditioning regimen, depending on the speciﬁc protocol. CNI alone or with
other immunosuppressants (mycophenolate mofetil, steroids, and metho-
trexate) was/were used for GVHD prophylaxis. Cord blood recipients
received cyclosporine A and methylprednisolone until December 2004, and
cyclosporine A plus mycophenolate mofetil thereafter. The diagnosis of
acute and chronic GVHDwas based on standard clinical criteria and biopsies
when available [18]. Acute GVHDwith grade II or above was controlled with
steroids, mainly methylprednisolone.
Statistical Analyses
Categorical variables were compared using Fisher’s exact test or
chi-square test. Continuous variables were compared using the Mann-
Whitney U test. Differences in clinical features between CNI-related
neurotoxicity group and noneCNI-related neurotoxicity group were
compared by univariate analysis. For convenience, we deﬁned noneCNI-
related neurotoxicity as all causes of neurologic complications except
CNI-related neurotoxicity. Multivariate logistic regression analysis was
performed to evaluate the risk factors for neurologic sequelae. We selected
variables which were well-known factors for neurologic complication, such
as age at HSCT, use of TBI, donor type, underlying disease type, CNI-related
neurotoxicity, severe acute GVHD (grade  3), and extensive chronic GVHD.
Cox proportional hazards analysis was used to evaluate the independent risk
factors for mortality. In model 1, we included variables with P values less
than .10 in the univariate analysis. In model 2, we included variables that
were identiﬁed as statistically signiﬁcant factors in model 1 as well as the
well-known risk factors for neurologic complication in the literature
because these well-known risk factors for neurologic complication might
effect mortality regardless of statistical signiﬁcance [7-13]. Multivariate
model 1 was adjusted for (1) age at HSCT, (2) days at neutrophil engraft-
ment, (3) use of ATG, (4) donor type (matched versus mismatched), (5)
extensive chronic GVHD, and (6) the existence of sequelae. Multivariate
model 2 was adjusted for following variables: (1) age at HSCT, (2) days at
neutrophil engraftment, (3) underlying disease type (malignant versus
nonmalignant), (4) use of TBI, (5) donor type (matched related versus un-
related and haploidentical), (6) acute GVHD (grade  3 versus no or grade I
and II GVHD), (7) extensive chronic GVHD, and (8) the existence of sequelae.
Days to neutrophil engraftment, extensive chronic GVHD, and the existence
of sequelae were included as variables in model 2 because they were
identiﬁed as signiﬁcant risk factors (P < .05) for mortality in model 1. The
cumulative incidence of neurologic complications and overall survival (OS)
were determined using Kaplan-Meier analysis with the log-rank method.
The null hypothesis of no difference was rejected if P values were less
than .05, or equivalently, if 95% conﬁdence intervals of the hazard ratio
excluded 1. The statistical analyses were performed using SPSS version 19
(SPSS, Chicago, IL) and GraphPad Prism version 6.04 (GraphPad Software, La
Jolla, CA).
RESULTS
Case Identiﬁcation and Baseline Characteristics
Between January 2000 and December 2012, a total of 383
pediatric patients underwent 430 cases of allogeneic HSCT.
Neurologic diagnostic tests were performed in 92 patients
(96 episodes) within 400 days after allogeneic HSCT. Patients
with pre-existing cerebral disorders (n ¼ 12), nonspeciﬁc or
mild neurologic symptoms (n ¼ 7), and head trauma (n ¼ 3)
were excluded. Finally, we identiﬁed 70 patients (73 epi-
sodes) as the neurologic complications group (Figure 1). The
median age at allogeneic HSCT was 10.1 years (range, .7 to
19.0 years) and the ratio of males to females was 1.9:1
(46:24). The median follow-up after allogeneic HSCT was 26
months (range, 1 to 143 months). Table 1 summarizes the
baseline characteristics of the study patients.
Clinical Features of Neurologic Complications
The cumulative incidences of neurologic complications at
days 30,100, 200, and 400 were 5.9%,12.3%,15.9%, and 20.0%,
respectively (Supplemental Figure 1). Almost two thirds of
the episodes (63.0%, 46 of 73) of neurologic complications
occurred within 100 days after allogeneic HSCT (Figure 2).
The etiologies of neurologic complications are listed in
Figure 1. Flow chart of case selection.
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etiology (47.9%, 35 of 73), followed by infectious disease
(11.0%, 8 of 73), CNS relapse of underlying disease (8.2%, 6 of
73), PTLD (6.8%, 5 of 73), metabolic disturbances (4.1%, 3 of
73), vascular disorders (2.7%, 2 of 73), and others (19.2%,14 of
73). Among the 14 other episodes, 9 episodes (12.3%, 9 of 73)
were of unknown causes, 4 (5.5%, 4 of 73) were related to
chemotherapy, and 1 (1.3%, 1 of 73) was related to radio-
therapy. CNI-related neurotoxicity represented 58.7% of all
etiologies (27 of 46) occurring within 100 days after HSCT
and 29.6% of etiologies (8 of 27) occurring after day 100.
Seizure (50.7%, 37 of 73) was the most frequent neuro-
logic symptom, followed by abnormality of cranial nerve
(such as ophthalmoplegia, visual ﬁelds defect, or facial palsy;
11.0%, 8 of 73), headache (8.2%, 6 of 73), abnormality of pe-
ripheral nervous system (such as motor weakness or sensory
deﬁcit; 6.8%, 5 of 73) and tremor (6.8%, 5 of 73), altered levels
of consciousness (5.5%, 4 of 73), and others (11.0%, 8 of 73).
Seizurewas also themost frequent symptom (71.4%, 25 of 35)
in episodes with an etiology caused by CNI-related
neurotoxicity.
We evaluated the neurologic sequelae at 6 months after
the onset of neurologic complications. Thirty-one neurologic
episodes (42.5%, 31 of 73) had remaining neurologic sequelae.
Among these episodeswith sequelae,11 episodes (15.1%,11 of
73) remained mild, 6 episodes (8.2%, 6 of 73) remained
moderate, 4 episodes (5.5%4 of 73) remained severe sequelae,
and 10 patients (13.7%, 10 of 73 in episodes; 14.3%, 10 of 70 in
patients) died because of neurologic complication.
Two patients died before the assessment of sequelae, and
their causes of death were not associated with neurologic
complications. One patient died because of engraftment
failure and the other patient died from coronary artery ste-
nosis related to GVHD. We grouped these cases into un-
known group (Supplemental Table 2).
We analyzed the sequelae according to etiology. Among
the total of 35 CNI-related neurotoxicity episodes, 26 epi-
sodes (74.3%, 26 of 35) did not have any sequelae and 8 ep-
isodes (22.9%, 8 of 35) did. In the episodes of infectious
disease, 4 episodes did not have any sequelae and the other 4
episodes resulted in death. The reasons for death included 2
cases of invasive fungal diseases (1 proven and 1 possiblefungal infection by deﬁnition) and 2 cases of meningoen-
cephalitis by virus infection (1 cytomegalovirus and 1
varicella-zoster virus).
We also analyzed sequelae according to symptom. Among
the total of 37 seizure episodes, 22 episodes presented with
seizure (59.5%, 22 of 37) and did not have any sequelae
(among them, 19 episodes presented with only 1 single
seizure episode), whereas the other 15 episodes (40.5%, 15 of
37) had sequelae. In the episodes presenting with tremor,
among a total of 5 tremor episodes, 4 episodes subsided
within 6 months and 1 episode had persisting mild sequelae
(Supplemental Table 2).
Statistical Analyses of Clinical Features and Outcomes
CNI-related neurotoxicity versus noneCNI-related
neurotoxicity
There were no signiﬁcant differences in the baseline
characteristics, including the age, sex, underlying disease,
type of donor, source of stem cell, intensity of conditioning
regimen, and severity of GVHD between the 2 groups
(Table 1). Seizures occurred more frequently in the CNI-
related neurotoxicity group than in noneCNI-related
neurotoxicity group (67.5% versus 32.4%, P ¼ .001), and
neurologic sequelae were less frequent in CNI-related
neurotoxicity group than in noneCNI-related neurotoxicity
group (25.8% versus 74.2%, P ¼ .002). All cases with abnor-
mality of cranial nerve (n ¼ 8) occurred in the noneCNI-
related neurotoxicity group (P ¼ .005), whereas all cases of
tremor (n ¼ 5) occurred in the CNI-related neurotoxicity
group (P ¼ .022). The median onset of neurologic complica-
tions was earlier in CNI-related neurotoxicity group (day 44;
range, 3 to 377) than in the noneCNI-related neurotoxicity
group (day 105; range, 7 to 384) (P ¼ .009) (Table 3). We
also explored whether certain symptoms or the onset or
existence of neurologic sequelae were associated with other
speciﬁc etiologies; however, no deﬁnitive associations were
apparent, except for CNI-related neurotoxicity.
Risk factors for neurologic sequelae
In univariate analysis, CNI-related neurotoxicity was
associated with fewer episodes of neurologic sequelae than
noneCNI-related neurotoxicity (hazard ratio [HR], .19; 95%
Table 1
Patient Characteristics
Characteristic All CNI Non-CNI P Value
No. of neurologic episodes (%) 73 35 (47.9) 38 (52.1)
No. of patients (%)* 70
Male sex 48 (65.8) 21 (60.0) 27 (71.1) .30
Age at diagnosis, median (range), yr 8.6 (0-17.7) 6.5 (0-12.6) 9.8 (0-17.7) .10
Age at HSCT, median (range), yr 10.2 (.7-19.0) 8.3 (1.1-17.9) 10.9 (.7-19.0) .10
Underlying disease .40
ALL 19 (26.0) 7 (20.0) 12 (31.6)
AML 21 (28.8) 8 (22.9) 13 (34.2)
SAA 11 (15.1) 6 (17.1) 5 (13.2)
Others (malignant)y 11 (15.1) 7 (20.0) 4 (10.5)
Others (nonmalignant)z 11 (15.1) 7 (20.0) 4 (10.5)
No. of HSCT 1.00
1 59 (80.8) 28 (80.0) 31 (81.6)
2 14 (19.2) 7 (20.0) 7 (18.4)
Source of stem cells .50
BM 19 (26.0) 12 (34.3) 7 (18.4)
PB 20 (27.4) 9 (25.7) 11 (28.5)
CB 31 (42.5) 13 (37.1) 18 (47.4)
Combinedx 3 (4.1) 1 (2.9) 2 (5.3)
Type of donor .90
Matched related 9 (12.3) 4 (11.4) 5 (13.2)
Matched unrelated 35 (47.9) 18 (51.4) 17 (44.7)
Mismatched unrelated 25 (34.2) 11 (31.4) 14 (36.8)
Haploidentical 4 (5.5) 2 (5.7) 2 (5.3)
Myeloablative conditioning regimen 69 (94.5) 33 (94.3) 36 (94.7) 1.00
Use of TBI 31 (42.5) 15 (42.9) 16 (42.1) 1.00
Use of ATG 43 (58.9) 21 (60.0) 22 (57.9) 1.00
Use of ﬂudarabine 30 (41.1) 13 (37.1) 17 (44.7) .60
Use of busulfan 32 (43.8) 14 (40.0) 18 (47.4) .60
GVHD prophylaxis .30
CsA only 9 (12.3) 4 (11.4) 5 (13.2)
CsA þ MTX 25 (34.2) 14 (40.0) 11 (28.9)
CsA þ MMF 25 (34.2) 9 (25.7) 16 (42.1)
CsA þ steroid 10 (13.7) 7 (20.0) 3 (7.9)
Othersk 4 (5.5) 1 (2.9) 3 (7.9)
Days to neutrophil engraftment, median (range){ 16 (9-47) 15 (9-47) 16 (9-33)
Grade of acute GVHD .80
None 13 (17.8) 5 (14.3) 8 (21.1)
1-2 39 (53.4) 19 (54.3) 20 (52.6)
3 21 (28.8) 11 (31.4) 10 (26.3)
Extent of chronic GVHD .60
None 22 (30.1) 8 (22.7) 14 (36.8)
Limited 14 (19.2) 7 (20.0) 7 (18.4)
Extensive 28 (38.4) 15 (42.9) 13 (34.2)
Not applicable 9 (12.3) 5 (14.3) 4 (10.5)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; SAA, severe aplastic anemia; BM, bonemarrow; PB, peripheral blood; CB, cord blood;
CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil.
Data presented are n (%), unless otherwise indicated.
* There were 3 patients who had both CNI-related and noneCNI-related episodes. One patient had CNI and unknown etiology and 2 patients had both CNI and
infectious etiology.
y Includes 1 case of hemophagocytic lymphohistiocytosis, 2 cases of juvenile myelomonocytic leukemia, 2 cases of lymphoma, 2 cases of chronic myeloid
leukemia, and 4 cases of neuroblastoma.
z Includes 1 case of congenital dyserythropoietic anemia, 2 cases of Fanconi anemia, 2 cases of osteopetrosis, 3 cases of pure red cell aplasia, and 3 cases of
primary immunodeﬁciencies.
x Includes 1 BM þ PB and 2 PB þ CB.
k Includes 1 tacrolimus, 1 tacrolimus þ MMF, and 2 tacrolimus þ MTX.
{ Two cases of engraftment failure were not included in this result.
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variate analysis, we adjusted for age at HSCT, use of TBI,
donor type, underlying disease type, severe acute GVHD
(grade  3), and extensive chronic GVHD, as well as CNI-
related neurotoxicity. CNI-related neurotoxicity was still
identiﬁed as the only signiﬁcant factor that was associated
with fewer episodes of neurologic sequelae (HR, .23; 95% CI,
.07 to .75; P ¼ .015) (Supplemental Table 1).
Risk factors for mortality
Including cases with all causes of death, the age at allo-
geneic HSCT, days to neutrophil engraftment after allogeneic
HSCT, extent of chronic GVHD, and the existence ofneurologic sequelae were regarded as variables (P < .10) to
evaluate in the multivariate analysis. Days to neutrophil
engraftment after HSCT and the existence of neurologic
sequelae had a signiﬁcant hazard effect on mortality (HR,
1.06; 95% CI, 1.01 to 1.12; P ¼ .019; and HR, 3.04; 95% CI, 1.33
to 6.96; P ¼ .008, respectively). In the mortality group, the
median time to neutrophil engraftment was 16 (range, 9 to
47) days, whereas it was 13.5 days in the survival group
(range, 9 to 21). We reanalyzed those data after excluding 11
patients who died because of disease progression. Age at
HSCT, days to neutrophil engraftment, use of ATG, donor type
(matched versus mismatched), extensive chronic GVHD, and
the existence of sequelae were regarded as variables (P< .10)
Figure 2. Onset of neurologic complications after allogeneic HSCT according to etiologies.
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variate model 1, days to neutrophil engraftment after HSCT,
extensive chronic GVHD, and neurologic sequelae were sig-
niﬁcant risk factors for mortality (HR, 1.07; 95% CI, 1.01 to
1.14; P ¼ .022; HR, 7.03; 95% CI, 2.05 to 24.15; P ¼ .002; and
HR, 5.02; 95% CI, 1.30 to 19.34; P ¼ .019, respectively). In
multivariate model 2, days to neutrophil engraftment after
HSCT, extensive chronic GVHD, and neurologic sequelae
were also identiﬁed as signiﬁcant risk factors for mortality
(HR, 1.08; 95% CI, 1.02 to 1.15; P ¼ .011; HR, 5.98; 95% CI, 1.71
to 20.90; P¼ .005; andHR, 4.37; 95% CI,1.12 to 17.05; P¼ .034,
respectively) (Table 4).
Ten patients died from direct neurologic complications
within 6 months of developing the neurologic episode
(Supplemental Table 2). Among those, 2 patients died of CNS
relapse. Of the remaining 8 patients, 4 patients with exten-
sive chronic GVHD died of direct CNS causes, including CMVTable 2
Etiology of Neurologic Complications
Etiology No. of episodes,
n (%)
Median onset, (range), d
CNI-related neurotoxicity 35 (47.9) 44 (3-377)
Infectious disease 8 (11.0) 146.5 (10-286)
Virus* 4 129 (10-154)
Bacteria 0
Fungusy 2 243.5 (201-286)
Unidentiﬁed originz 2 101 (19-183)
CNS relapse 6 (8.2) 172 (66-347)
PTLD (CNS involvement) 5 (6.8) 155 (54-209)
Metabolic disturbance 3 (4.1) 79 (35-268)
Vascular eventx 2 (2.7) 53 (47-59)
Othersk 14 (19.2) 87.5 (7 to 384)
Total 73 62 (7 to 384)
* Includes 1 cases of Human herpesvirus type 6 meningitis, 1 case of
varicella-zoster virus encephalitis, and 2 cases of cytomegalovirus diseases
(encephalitis, ventriculitis).
y Includes 1 proven case of invasive Aspergillosis disease, and 1 possible
case of invasive fungal disease.
z Includes 1 case of cavernous sinusitis and 1 case of meningitis, in which
the pathogens were not proven.
x Includes 1 case of subdural hemorrhage and 1 case of intracranial
hemorrhage with subdural hemorrhage.
k Includes 1 case of radiotherapy-related neurotoxicity, 4 cases of
chemotherapy-related neurotoxicity, and 9 unknown cases.encephalitis, CNS aspergillosis, brain abscess, and dissemi-
nated PTLD involving the CNS. Three patients without
extensive chronic GVHD died of varicella-zoster virus en-
cephalitis (n ¼ 1) and disseminated PTLD with CNS
involvement (n ¼ 2).
When we looked at the mortality data for all patients
beyond 6 months (data not shown), 25 patients with
neurologic complication died. Twelve patients with
extensive chronic GVHD died (48%). Among them, 6 (50%)
died of GVHD itself and 3 (25%) died of CNS infection. In
patients who died with neurologic sequelae (n ¼ 15), 5
patients (33.3%) died of severe acute or extensive chronic
GVHD and 4 patients (26.7%) died of CNS infection. Out of
25 patients, 11 patients had newly developed neurologic
symptoms, including intractable seizure (n ¼ 6), decreased
level of consciousness (n ¼ 2), ophthalmoplegia (n ¼ 1),
decreased visual activity (n ¼ 1), and ascending paralysis
(n ¼ 1) within 4 weeks before death.
Overall survival
The 5-year OS rate was signiﬁcantly lower in neurologic
complications group than in group without neurologic com-
plications (44.6% in the neurologic complications group versus
61.8% in group without neurologic complications, P ¼ .013)
(Figure 3A). Among the neurologic complications group, the
5-year OS rate showed almost a 2-fold difference depending
on the existence of neurologic sequelae (29.7% in sequelae
group versus 56.9% in the without-sequelae group, P ¼ .007)
(Figure 3B). After the exclusion of 11 of deaths due to disease
progression, the 5-year OS rate showed a similar difference
between 2 groups (37.1% in sequelae group versus 73.2% in
without-sequelae group, P ¼.015) (Supplemental Figure 2).
There were no signiﬁcant differences in the 5-year OS rate
between the group with neurologic complications without
sequelae and the group without any neurologic complications
(57.3% versus 61.8%, P ¼ .906) (Figure 3C), and between the
CNI-related neurotoxicity and noneCNI-related neurotoxicity
groups (61.6% versus 33.3%, P ¼ .087).
DISCUSSION
The main ﬁnding of this study is the identiﬁcation of risk
factors for mortality in pediatric recipients with neurologic
Table 4
Multivariate Analysis for Mortality in Patients with Neurologic
Complications
Variable Model 1 Model 2
HR 95% CI P HR 95% CI P
Excludes 11 patients who died due to disease progression (n ¼ 59)
Age at HSCT 1.03 .92-1.16 .586 1.02 .91-1.15 .712
Days to neutrophil
engraftment after
HSCT
1.07 1.01-1.14 .022 1.08 1.02-1.15 .011
Underlying disease
Malignant versus nonmalignant .73 .17-3.08 .664
Conditioning regimen
TBI versus non-TBI .94 .24-3.70 .944
ATG versus non-
ATG
1.85 .45-7.61 .393
Donor type
Matched related
versus others*
.0y 0-. .979
Matched versus
mismatched
.74 .19-2.92 .666
Severe acute GVHD
(grade  3)
.94 .27-3.33 .929
Extensive chronic
GVHD
7.03 2.05-24.15 .002 5.98 1.71-20.90 .005
Sequelae 5.02 1.30-19.34 .019 4.37 1.12-17.05 .034
Multivariate model 1 was adjusted for age at HSCT, days to neutrophil
engraftment, use of ATG, donor type (matched versus mismatched),
extensive chronic GVHD, and the existence of sequelae; multivariate model
2 was adjusted for age at HSCT, days to neutrophil engraftment, use of TBI,
donor type (matched related versus unrelated and haploidentical), exten-
sive chronic GVHD, and the existence of sequelae.
* Includes matched unrelated, mismatched unrelated, and haploidentical
donors.
y There were 9 matched related donors included in our study. Among
them, 3 CNS relapse cases were excluded in mortality analysis and the
remaining 6 cases all lived.
Table 3
Clinical Differences of Neurologic Complications between the CNI-Related
Neurotoxicity Group and the NoneCNI-Related Neurotoxicity Group
CNI
(n ¼ 35)
Non-CNI
(n ¼ 38)
P Value
Symptom
Seizure 25 (71.4) 12 (31.6) .001
Headache 0 6 (100) .026
Altered level of consciousness 2 (50.0) 2 (50.0) 1.00
CN abnormality 0 8 (100) .005
PN abnormality 0 5 (100) .055
Tremor 5 (100) 0 .022
Others* 3 (37.5) 5 (62.5) .712
Median onset after HSCT,
(range), d
44 (3-377) 105 (7 to 384) .009
Within 100 d 27 (58.7) 19 (41.3) .028
After 100 d 8 (29.6) 19 (70.4)
Association of fever 16 (57.1) 12 (42.9) .238
Sequelae 8 (25.8) 23 (74.2) .002
CN indicates cranial nerve; PN, peripheral nerve.
* Includes 1 case of dysarthria with paresthesia, 1 case of amnesia, 1 case
of chorea, 1 case of vertigo, 1 case of delirium, 1 case of anxiety with irri-
tability, and 2 cases of ataxia.
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complications caused by CNI-related neurotoxicity have
certain distinct clinical features.
The cumulative incidence of neurologic complications at
1 year was 20.0% (95% CI, 15.7% to 24.23%). In the literature,
the incidence of neurologic complications was reported with
a range from 9.7% to 65%. This wide range may be due to the
heterogeneity of study populations and extensive variation
in deﬁnitions of neurologic complications [4,6-14]. If the
severity was conﬁned to clinically signiﬁcant neurologic
complications (CTCAE grade 3 and above, or possibly
assumed), the incidence ranges from 9.7% to 23% at around 6
to 12 months after HSCT [4,6,7,9,12]. Considering the
extended setting of this study (CTCAE grade 2 and above), the
incidence might be underestimated but comparable. Almost
two thirds of neurologic complications (63.0%, 46 of 73)
occurred within 100 days after allogeneic HSCT. CNI-related
neurotoxicity was the most common etiology (Figure 2).
Faraci et al. reported a similar pattern of onset and frequency
of the etiologies in 37 children with severe CNS complica-
tions (CTCAE grade 3 or 4) after HSCT regardless of the type
of HSCT [9]. We found similar results in a larger and more
homogenous study population.
CNI-related neurotoxicity has been reported to be 1 of the
most frequent neurologic complications after allogeneic
HSCT [3,6,9,12]. It has been suggested that CNI-induced
endothelial damage causes subcortical edema in the poste-
rior circulation by hyperperfusion injury and by the lack of
autoregulation [19,20]. In our study, CNI-related neurotox-
icity was signiﬁcantly associated with seizure and tremor
that occurred as earlier onset events. It also showed a sig-
niﬁcant association with lower probability of headache, ab-
normalities in cranial nerves, and neurologic sequelae
(Tables 1 and 3). However, it did not inﬂuence OS. In our
study, having neurologic sequelae was identiﬁed as signiﬁ-
cant risk factor for mortality in patients with neurologic
complications (Tables 3 and 4).
Because CNI-related neurotoxicity was associated with a
lower probability of neurologic sequelae, we examined
whether this was related to decreased mortality. However,
there was no statistically signiﬁcant difference in a 5-year OS
rate between CNI-related neurotoxicity group and noneCNI-
related neurotoxicity group (61.6% versus 33.3%, P ¼ .087).Koh et al. and Iguchi et al. also reported that there was no
signiﬁcant difference in the long-term survival between CNI
and non-CNI groups [8,12]. In contrast, Siegal at el. reported
inferior 1-year survival in patients with PRES, which was
mainly caused by CNI. Although our analysis did not detect
any statistically signiﬁcant difference, OS of the CNI-related
neurotoxicity group appears to be nearly twice that of the
noneCNI-related neurotoxicity group. To clarify the associ-
ation between CNI and prognosis, further well-designed
cohort studies are needed.
Neurologic complications after HSCT increase mortality.
Siegal et al. retrospectively analyzed CNS complications
occurring within 100 days after allogeneic HSCT in 302 adult
recipients and reported a 1-year survival of 28% and 72% in
patients with andwithout CNS complications, respectively (P
< .001) [6]. Koh et al. reported a lower 5-year OS rate in
pediatric recipients with CNS complications compared with
their counterparts (52.1% versus 64.9%, P¼ .014) [12]. In cases
of neurologic sequelae, we could not ﬁnd any studies that
analyzed the association between neurologic sequelae and
mortality, except 1 descriptive study of late sequelae [21].
We also found increased mortality in patients with
neurologic complications compared with patients without
neurologic complications. Among the former, patients with
sequelae showed signiﬁcantly higher mortality than patients
without sequelae (Figure 3B). In multivariate analysis, we
conﬁrmed that the existence of neurologic sequelae and
extensive chronic GVHD were major signiﬁcant risk factors
for mortality in patients with neurologic complications after
allogeneic HSCT. Days to neutrophil engraftment also
appeared to be a risk factor with an HR of 1.08 (95% CI, 1.02 to
1.15; P ¼ .011).
Figure 3. (A) Overall survival between neurologic complications group and the
group without neurologic complications. (B) Overall survival between the
sequelae group and the group without sequelae in patients with neurologic
complications. (C) Overall survival between the group with neurologic compli-
cations without sequelae and the group without any neurologic complications.
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First, as we mentioned earlier, the survival rate in the CNI-
related neurotoxicity group was higher than that of the
noneCNI-related neurotoxicity group. Second, there was
no signiﬁcant difference in the survival rate between pa-
tients who had neurologic complications without sequelae
and those without neurologic complications. This in-
dicates that if neurologic complication did not persist 6
months after onset, there was no signiﬁcant effect on
mortality.
Of note, in addition to severe GVHD, CNS pathologies,
particularly CNS infection and CNS involving PTLD, appear to
be important risks for mortality. As a possible explanation,
severe immunosuppression to control GVHD might have
contributed to the development of these CNS pathologies.
Therefore, it appears that GVHD and CNS pathologies are
inter-related for increased mortality.
This study had limitations. First, it was a retrospective
study andmainly included data about brain-imaging studies.To minimize this measurement bias, we also included data
for nerve conduction study. However, this might be insufﬁ-
cient to represent all the peripheral nervous system episodes
when compared with CNS episodes. Furthermore, the grade
of adverse events might be related to the severity of
sequelae. However, because of insufﬁcient data in the med-
ical records, we could not analyze the association. Finally, the
number of episodes with CNI-associated neurotoxicity could
have been overestimated. Currently, there is no clear deﬁ-
nition or guideline on CNI-related neurotoxicity. We identi-
ﬁed CNI-associated neurotoxicity cases as a diagnosis of
exclusion in symptomatic recipient with abnormal brain-
imaging ﬁndings, such as PRES or toxic encephalopathy.
However, we did not routinely perform pre-HSCT brain im-
aging studies in all recipients. Brain white matter abnor-
malities could have already existed in asymptomatic patients
before HSCT.
Nevertheless, this study has several strengths. First, this is
the ﬁrst study to analyze the neurologic sequelae and the risk
factors for mortality in pediatric recipients of allogeneic
HSCT with neurologic complications. Second, we tried to use
standardized and authorized measurement tools to allow for
easier comparison with further studies. Third, we identiﬁed
the clinical features of CNI-associated neurotoxicity in a large
pediatric population.
In conclusion, neurologic complication commonly occurs
in pediatric HSCT recipients. Major signiﬁcant risk factors for
mortality in pediatric recipients with neurologic complica-
tion were the existence of neurologic sequelae and extensive
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